Aarti Pharmalabs Limited (NSE:AARTIPHARM)
India · Delayed Price · Currency is INR 828.30
+2.55 (0.31%)
Sep 11, 2026, 3:29 PM IST
Aarti Pharmalabs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 19,690 | 18,194 | 21,151 | 18,526 | 19,452 | 11,999 | |
Revenue Growth | 1.20% | -13.98% | 14.17% | -4.76% | 62.11% | - |
Cost of Revenue | 9,020 | 8,838 | 11,232 | 10,608 | 12,046 | 7,470 |
Gross Profit | 10,670 | 9,357 | 9,919 | 7,918 | 7,406 | 4,529 |
Selling, General & Admin | 1,822 | 1,787 | 1,658 | 1,463 | 1,349 | 852.03 |
Other Operating Expenses | 4,450 | 3,545 | 3,617 | 2,598 | 2,637 | 1,608 |
Operating Expenses | 7,388 | 6,376 | 6,144 | 4,790 | 4,611 | 2,881 |
Operating Income | 3,282 | 2,981 | 3,775 | 3,128 | 2,795 | 1,648 |
Interest Expense | -529.83 | -469.03 | -268.96 | -172.15 | -210.52 | -3.4 |
Interest & Investment Income | - | 21.39 | 71.47 | 30.74 | 21.87 | 24.84 |
Earnings From Equity Investments | 172 | 79.98 | - | - | - | - |
Currency Exchange Gain (Loss) | -259.34 | -332.08 | 16.93 | - | - | - |
Other Non Operating Income (Expenses) | 94.28 | 76.08 | 12.71 | 12.52 | 1.85 | -116.1 |
EBT Excluding Unusual Items | 2,760 | 2,357 | 3,607 | 2,999 | 2,608 | 1,554 |
Gain (Loss) on Sale of Investments | - | - | - | 5.51 | - | - |
Gain (Loss) on Sale of Assets | - | - | 0.08 | 0.19 | -0.58 | 0.21 |
Other Unusual Items | -27.95 | -27.95 | - | - | - | - |
Pretax Income | 2,732 | 2,329 | 3,607 | 3,005 | 2,608 | 1,554 |
Income Tax Expense | 683.45 | 582.14 | 882.85 | 835.9 | 672.78 | 331.29 |
Net Income | 2,048 | 1,747 | 2,724 | 2,169 | 1,935 | 1,223 |
Net Income to Common | 2,048 | 1,747 | 2,724 | 2,169 | 1,935 | 1,223 |
Net Income Growth | -23.13% | -35.87% | 25.59% | 12.10% | 58.27% | - |
Shares Outstanding (Basic) | 91 | 91 | 91 | 91 | 91 | 91 |
Shares Outstanding (Diluted) | 91 | 91 | 91 | 91 | 91 | 91 |
Shares Change | 0.11% | 0.05% | 0.07% | 0.01% | - | 36150.40% |
EPS (Basic) | 22.59 | 19.27 | 30.06 | 23.93 | 21.35 | 13.49 |
EPS (Diluted) | 22.56 | 19.25 | 30.04 | 23.93 | 21.35 | 13.49 |
EPS Growth | -23.21% | -35.92% | 25.53% | 12.08% | 58.27% | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -1,474 | -718.98 | 607.5 | 1,480 | -1,849 |
Free Cash Flow Per Share | - | -16.25 | -7.93 | 6.70 | 16.33 | -20.40 |
Dividend Per Share | - | 3.500 | 5.000 | 3.000 | 2.000 | - |
Dividend Growth | - | -30.00% | 66.67% | 50.00% | - | - |
Gross Margin | 54.19% | 51.43% | 46.90% | 42.74% | 38.07% | 37.74% |
Operating Margin | 16.67% | 16.38% | 17.85% | 16.89% | 14.37% | 13.74% |
Profit Margin | 10.40% | 9.60% | 12.88% | 11.71% | 9.95% | 10.19% |
Free Cash Flow Margin | - | -8.10% | -3.40% | 3.28% | 7.61% | -15.40% |
EBITDA | 4,396 | 3,796 | 4,539 | 3,804 | 3,421 | 2,069 |
EBITDA Margin | 22.32% | 20.87% | 21.46% | 20.54% | 17.58% | 17.25% |
D&A For EBITDA | 1,113 | 815.61 | 764.05 | 676.32 | 625.43 | 421.19 |
EBIT | 3,282 | 2,981 | 3,775 | 3,128 | 2,795 | 1,648 |
EBIT Margin | 16.67% | 16.38% | 17.85% | 16.89% | 14.37% | 13.74% |
Effective Tax Rate | 25.02% | 24.99% | 24.48% | 27.82% | 25.80% | 21.32% |
Revenue as Reported | 19,785 | 18,292 | 21,235 | 18,575 | 19,476 | 12,025 |
Advertising Expenses | - | 37.9 | 26.39 | 64.11 | 51.61 | - |